Diabetes patients in the US will have greater flexibility in managing insulin delivery after Insulet announced its Omnipod pump is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous ...
Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...
Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out ...
Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...
The Abbott FreeStyle Libre 2 can be used as a real-time continuous glucose monitor (CGM) with an upgrade to the FreeStyle LibreLink app. Please note, the below information comes with a critical update ...
Abbott announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received approval fromHealth Canada for adults and children (4 and older) with diabetes. With new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results